[Cannabinoid mouth spray brought help to a severely spastic young man].

Authors
Category Primary study
JournalDuodecim; laaketieteellinen aikakauskirja
Year 2014
Cannabinoid was licensed in 2012 for the treatment of spasticity associated with multiple sclerosis in Finland. Spasticity is one of the main symptoms in cerebral palsies and a risk factor of multiple painful anomalies of the skeletal network. We describe a 28-year-old man with severe cerebral palsy, whose quality of life improved and the need for help decreased by using two daily mouth sprays of cannabinoid.
Epistemonikos ID: 8d153f07323c6d9f2a2d04f266529437a424b803
First added on: Jan 28, 2022